Contaminated Peptides from Commercial Suppliers Can Produce False-Positive Results in Vaccine Trials

Researchers analyzed T-cell assay results from HIV peptide library stimulation experiments and noticed suspicious CD8+ T-cell responses. They investigated the responding T-cell frequency and HLA restriction patterns, which pointed to a non-HIV peptide as the trigger. Analytical characterization (likely mass spectrometry) of the original peptide stock confirmed the presence of the HCMV contaminant. The team then developed a proposed biological quality assurance/quality control protocol to supplement standard biochemical testing.

Vaccine clinical trials rely on immune assays that use synthetic peptides to determine whether a vaccine works. If those peptides are contaminated, the trial could wrongly conclude a vaccine is effective. This study exposed a systemic quality problem in commercial peptide manufacturing that could affect any clinical trial using peptide-based immune assays — not just HIV vaccine studies.

As peptide libraries become central to immunology research and vaccine development, the purity of commercial synthetic peptides becomes a clinical issue, not just an academic one. This study highlighted a gap in quality control that the field has since worked to address. The findings have implications for any research program that depends on peptide stimulation assays, from cancer immunotherapy to infectious disease vaccines.

The study identified contamination in peptide sets from two suppliers but did not survey the broader commercial peptide manufacturing landscape. The frequency of this type of cross-contamination across the industry remains unknown. The proposed QA/QC protocols add cost and complexity to already expensive clinical trial workflows.